HRS-9231

DRUG3 trials

Sponsors

Shanghai Shengdi Pharmaceutical Co., Ltd, Jiangsu HengRui Medicine Co., Ltd.

Conditions

Contrast-Enhanced Magnetic Resonance Imaging DetectionFor Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) LesionsHealthy Volunteers

Phase 1

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

CompletedNCT06657560

Shanghai Shengdi Pharmaceutical Co., LtdContrast-Enhanced Magnetic Resonance Imaging Detection

Start: 2024-10-14End: 2025-07-03Updated: 2025-07-18

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

CompletedNCT07123376

Shanghai Shengdi Pharmaceutical Co., LtdHealthy Volunteers

Start: 2024-06-05End: 2024-10-06Updated: 2025-08-14

Phase 2

A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Not yet recruitingNCT06731829

Jiangsu HengRui Medicine Co., Ltd.For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions

Start: 2024-12-31End: 2025-04-30Target: 78Updated: 2024-12-12

Related Papers

Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.

2026-08-22